RTT

Trumpet Adds Service Areas & Autism Treatment Centers in Ohio

Retrieved on: 
Thursday, October 24, 2019
Psychiatry, Abnormal psychology, Health, Autism, Psychiatric diagnosis, RTT, Geraldine Dawson, Autism Speaks

LAKEWOOD, Colo., Oct. 24, 2019 /PRNewswire/ -- Trumpet Behavioral Health ("Trumpet") is a leading autism treatment provider that helps children, teens, and adolescents with autism reach their full potential.

Key Points: 
  • LAKEWOOD, Colo., Oct. 24, 2019 /PRNewswire/ -- Trumpet Behavioral Health ("Trumpet") is a leading autism treatment provider that helps children, teens, and adolescents with autism reach their full potential.
  • To help more families gain access to experienced, compassionate, and comprehensive autism care, Trumpet is opening new treatment centers in Columbus and Cincinnati and expanding services to Cleveland.
  • Since the Ohio Autism Insurance Coverage Mandate became law in January 2019, demand for Trumpet's high-quality autism care has grown.
  • By expanding service areas and adding new centers, Trumpet hopes to help more families gain access to high-quality autism services.

Supernus to Host Third Quarter 2019 Earnings Conference Call

Retrieved on: 
Thursday, October 24, 2019
Anticonvulsants, RTT, Organic compounds, Chemistry, Organ systems, Oxcarbazepine, Topiramate, XR, Epilepsy in animals

Following the live call, a replay will be available on the Companys website under the Investors Relations section.

Key Points: 
  • Following the live call, a replay will be available on the Companys website under the Investors Relations section.
  • The webcast will be available on the Companys website for 60 days following the live call.
  • Supernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
  • The Company currently markets Trokendi XR (extended-release topiramate) for the prophylaxis of migraine and the treatment of epilepsy, and Oxtellar XR (extended-release oxcarbazepine) for the treatment of epilepsy.

The Medicines Company to Announce Third Quarter 2019 Financial Results on October 30

Retrieved on: 
Thursday, October 24, 2019
Biotechnology, Other Health, Health, Pharmaceutical, Cardiology, Lipids, Medical specialties, Branches of biology, RTT, Sterols, Cardiology, Lipoproteins, Nutrition, Low-density lipoprotein, Cholesterol, Atherosclerosis, Cardiovascular disease

The Medicines Company (NASDAQ: MDCO) is a biopharmaceutical company with a singular, relentless focus on addressing the greatest global healthcare challenge and burden today cardiovascular disease.

Key Points: 
  • The Medicines Company (NASDAQ: MDCO) is a biopharmaceutical company with a singular, relentless focus on addressing the greatest global healthcare challenge and burden today cardiovascular disease.
  • Our purpose is to halt the deadly progression of atherosclerosis and the cardiovascular risk created by high levels of LDL cholesterol.
  • The Company is headquartered in Parsippany, New Jersey.
  • For more information, please visit www.themedicinescompany.com and follow us on Twitter @MDCONews and LinkedIn .

Joint Statement from the Canadian Association of Gastroenterology and Crohn's and Colitis Canada

Retrieved on: 
Thursday, October 24, 2019
Medical specialties, Medicine, Health, Autoimmune diseases, Abdominal pain, RTT, Gastrointestinal tract disorders, Crohn's and Colitis Canada, Biopharmaceutical, Crohn's disease, Inflammatory bowel disease, Gastroenterology

TORONTO, Oct. 24, 2019 /CNW/ -The Canadian Association of Gastroenterology and Crohn's and Colitis Canada today announced a joint statement that has been accepted for publication in the Journal of the Canadian Association of Gastroenterology.

Key Points: 
  • TORONTO, Oct. 24, 2019 /CNW/ -The Canadian Association of Gastroenterology and Crohn's and Colitis Canada today announced a joint statement that has been accepted for publication in the Journal of the Canadian Association of Gastroenterology.
  • The paper, entitled Joint Canadian Association of Gastroenterology and Crohn's and Colitis Canada Position Statement on Biosimilars for the Treatment of Inflammatory Bowel Disease , was co-authored by esteemed Canadian gastroenterologists including: Drs Paul Moayyedi, Eric Benchimol, David Armstrong, and Grigorios I. Leontiadis.
  • Using the GRADE approach, authors reviewed evidence comparing biosimilars (available in Canada) to originator biologics for the treatment of patients with inflammatory bowel disease.
  • "We are hopeful that this joint statement gives government pause and opens up discussion toward alternate policy interventions."

Melinta Therapeutics Announces U.S. FDA Approval of Supplemental New Drug Application for BAXDELA® (delafloxacin) for the Treatment of Community-Acquired Bacterial Pneumonia (CABP)

Retrieved on: 
Thursday, October 24, 2019
Chemical compounds, Organic compounds, RTT, Fluoroquinolone antibiotics, Merck, Cyclopropanes, Moxifloxacin, Skin and skin structure infection, Antibiotics, Tedizolid, Lipoglycopeptide

We are pleased to announce the approval of BAXDELA for the treatment of CABP in adults, said Jennifer Sanfilippo, interim chief executive officer of Melinta.

Key Points: 
  • We are pleased to announce the approval of BAXDELA for the treatment of CABP in adults, said Jennifer Sanfilippo, interim chief executive officer of Melinta.
  • The FDA approval of BAXDELA for the treatment of CABP is based on positive results from a Phase III, randomized, double-blind, study that compared the efficacy and safety of BAXDELA to moxifloxacin.
  • BAXDELA was approved by the FDA in 2017 for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria.
  • The most common adverse reactions (incidence 2%) in patients treated with BAXDELA are nausea, diarrhea, headache, transaminase elevations, and vomiting.

DBV Technologies to Highlight the Burden of Peanut Allergy and Patient Experiences with Viaskin Peanut at ACAAI 2019

Retrieved on: 
Thursday, October 24, 2019
Medical specialties, Medicine, Food allergies, RTT, Allergology, Immune system, Immunology, Peanut allergy, Peanut, Tree nut allergy, Allergy, Ara h1

Peanut allergy places a significant burden on both patients and their families, often due to uncertainty around accidental exposure.

Key Points: 
  • Peanut allergy places a significant burden on both patients and their families, often due to uncertainty around accidental exposure.
  • Viaskin Peanut is the Companys lead product candidate designed to potentially reduce the risk of life-threatening allergic reactions due to accidental exposure to peanuts.
  • An investigational non-invasive, once-daily, epicutaneous patch, Viaskin Peanut seeks to deliver microgram quantities of peanut antigen to activate the immune system.
  • DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg.

Asia Pacific Diabetes Care Devices Market Report 2019-2027 - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 24, 2019
Diabetes, Health, Medical devices, Organ systems, RTT, Endocrine system, Endocrinology, Diabetes, Diabetes management, Minimed Paradigm

The "Asia Pacific Diabetes Care Devices Market to 2027 - Regional Analysis and Forecasts by Product; End User; and Country" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Asia Pacific Diabetes Care Devices Market to 2027 - Regional Analysis and Forecasts by Product; End User; and Country" report has been added to ResearchAndMarkets.com's offering.
  • The Asia Pacific diabetes care devices market is expected to reach US$ 8,880.7 Mn in 2027 from US$ 5,011.5 Mn in 2018.
  • The growth of the diabetes care devices market is primarily attributed to the rapid technological advancements in diabetes care devices and increasing rate of obesity.
  • In 2018, the glucose monitoring devices segment held a largest market share of 54.0% of the diabetes care devices market, by product.

Healthfirst Offers Members Free Flu Shots

Retrieved on: 
Thursday, October 24, 2019
RTT, Infectious diseases, Medical specialties, Medicine, Influenza vaccine, Vaccines, Influenza, Flu season, Flu pandemic in the United Kingdom

Healthfirst members can schedule an appointment for a free flu shot with their doctor, or go to a participating pharmacy or local urgent care center.

Key Points: 
  • Healthfirst members can schedule an appointment for a free flu shot with their doctor, or go to a participating pharmacy or local urgent care center.
  • There is no need for Healthfirst members to travel far to get vaccinated.
  • There is no reason to delay; free flu shots are available now."
  • Five tips to stay flu free this season:
    Get a flu shot!

Lupus Research Alliance Announces 2019 Distinguished Innovator Awards Aimed at New Lupus Treatments

Retrieved on: 
Thursday, October 24, 2019
Medical specialties, Medicine, Health, Autoimmune diseases, RTT, Cutaneous lupus erythematosus, Systemic lupus erythematosus, Autoimmunity, Sjögren syndrome, Lupus

NEW YORK, Oct. 24, 2019 /PRNewswire/ --The Lupus Research Alliance proudly announces two exceptional recipients of the 2019 Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity:Fabienne Mackay, PhD, and Jeffrey Rathmell, PhD.

Key Points: 
  • NEW YORK, Oct. 24, 2019 /PRNewswire/ --The Lupus Research Alliance proudly announces two exceptional recipients of the 2019 Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity:Fabienne Mackay, PhD, and Jeffrey Rathmell, PhD.
  • With her Distinguished Innovator Award, Dr. Mackay and her team plan to test a novel combination approach to reverse lupus in mice.
  • Their research is expected to accelerate the development of novel treatments that prevent, arrest, or cure lupus and its complications.
  • The Lupus Research Alliance aims to transform treatment while advancing toward a cure by funding the most innovative lupus research in the world.

Parent Project Muscular Dystrophy Awards $148,000 in Grants to Nationwide Children's Hospital and University of Missouri to Improve Cardiac Function in Duchenne Muscular Dystrophy

Retrieved on: 
Thursday, October 24, 2019
RTT, Muscular dystrophy, Organ systems, Branches of biology, Dystrophin, Cardiomyopathy, Duchenne muscular dystrophy, Draft:CureDuchenne

The absence of dystrophin in the heart contributes to a progressive deterioration of cardiac muscle and eventual cardiomyopathy.

Key Points: 
  • The absence of dystrophin in the heart contributes to a progressive deterioration of cardiac muscle and eventual cardiomyopathy.
  • Abby Bronson, PPMD's Senior Vice President of Research Strategy, explains why funding the cardiac research of Drs.
  • Hor and Duan is so critical: "The leading cause of death among people with Duchenne is heart disease.
  • There is also evidence that women who are carriers of Duchenne are at risk of heart disease.